Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An infrequent esophageal carcinoma arising from esophageal glands. (WHO)
No clinical trials have been registered for esophageal adenoid cystic carcinoma.
15 publications have been identified in PubMed for esophageal adenoid cystic carcinoma. Research spans Case Report / Case Series (67%), Clinical Trial Publication (27%), and Basic Science / Preclinical (7%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 10 | 67% |
Data assembled from 2 of 12 sources · Last updated Nov 2, 2026, 3:59 PM UTC
Clinical study results
4 |
27% |
Laboratory research | 1 | 7% |
Bombon MF (2026). [PMID: 41873313](https://pubmed.ncbi.nlm.nih.gov/41873313/). *Cureus*. [Case Report / Case Series]
Wu AQ (2026). [PMID: 41768241](https://pubmed.ncbi.nlm.nih.gov/41768241/). *Frontiers in oncology*. [Case Report / Case Series]
Ma C (2026). [PMID: 41939755](https://pubmed.ncbi.nlm.nih.gov/41939755/). *Frontiers in medicine*. [Case Report / Case Series]
Bai Y (2026). [PMID: 42255219](https://pubmed.ncbi.nlm.nih.gov/42255219/). *Front Oncol*. [Case Report / Case Series]
Ayed MB (2025). [PMID: 39807115](https://pubmed.ncbi.nlm.nih.gov/39807115/). *Radiology case reports*. [Basic Science / Preclinical]
Sheng Y (2025). [PMID: 40756950](https://pubmed.ncbi.nlm.nih.gov/40756950/). *International journal of particle therapy*. [Clinical Trial Publication]
Constantin AA (2025). [PMID: 40361873](https://pubmed.ncbi.nlm.nih.gov/40361873/). *Diagnostics (Basel, Switzerland)*. [Case Report / Case Series]
Li W (2025). [PMID: 41242959](https://pubmed.ncbi.nlm.nih.gov/41242959/). *Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery*. [Clinical Trial Publication]
Lu Z (2025). [PMID: 41278292](https://pubmed.ncbi.nlm.nih.gov/41278292/). *Frontiers in oncology*. [Case Report / Case Series]
Hao X (2025). [PMID: 41020933](https://pubmed.ncbi.nlm.nih.gov/41020933/). *Revista espanola de enfermedades digestivas*. [Case Report / Case Series]
AI-curated news mentioning esophageal adenoid cystic carcinoma
Updated Oct 19, 2026
Remix Therapeutics is advancing its lead program, REM-422, targeting adenoid cystic carcinoma, a rare cancer with no approved therapies. The company focuses on small molecule medicines that correct RNA splicing errors linked to various serious conditions.
A recent SEER analysis provides updated insights into the demographics, clinical features, and survival rates of patients with adenoid cystic carcinoma. This study compares outcomes in major and minor salivary glands versus non-salivary sites, enhancing understanding of this rare cancer.
A recent case series published on PubMed highlights findings from 26 patients with adenoid cystic carcinoma of the breast. This research contributes to the understanding of this rare breast cancer subtype.
A rare case study highlights the clinical presentation and histopathological evaluation of adenoid cystic carcinoma in the male breast. This research contributes to the understanding of this uncommon malignancy.